Baxano Surgical (NASDAQ:BAXS) has a new chief financial officer lined up to replace Joe Slattery, who is resigning from the medical device company “to pursue another business opportunity.”
Slattery, who been CFO for the Raleigh company since 2010 when it was called TranS1, submitted his resignation on Monday. His resignation takes effect Sept. 27.
Tim Shannon, vice president of finance, will become interim CFO for Baxano. Shannon joined Baxano earlier this year. His experience includes working as vice president of financial reporting at Talecris Biotherapeutics and as CFO and Treasurer at Harris Wholesale. A certified public accountant, Shannon started his career at PricewaterhouseCoopers.
In other Baxano moves, the company appointed Greg Slusser vice president of commercial operations effective Oct. 7. Slusser comes Baxano from automated external defibrillator manufacturer Defibtech, where he was vice president of sales and marketing. Slusser has also held senior sales and marketing positions with American Medical Systems and Johnson & Johnson.
Baxano focuses on minimally invasive products to treat degenerative spinal conditions affecting the lumbar region. The company is the product of the merger of North Carolina company TranS1 with California-based Baxano. The combined company is managed by the former TranS1 team and is headquartered in Raleigh. Following the close of the merger in the spring, the combined company took the Baxano name.
